Trial Profile
A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide (Primary) ; Etoposide (Primary) ; Mitoxantrone (Primary) ; Prednisone (Primary) ; Procarbazine (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2024 Planned End Date changed from 30 Oct 2023 to 30 Oct 2024.
- 12 Aug 2020 Status changed from recruiting to active, no longer recruiting.
- 03 May 2019 Status changed from active, no longer recruiting to recruiting.